Comparative study of variations in blood pressure and heart rate among normotensive patients and hypertensive patients receiving angiotensin receptor blockers during surgery under spinal anesthesia

Author(s):  
Dinakar R ◽  
Narendranath Sanji ◽  
Ravishankar B ◽  
Vidya K ◽  
Shashikala H
2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Mohammad Saifur Rohman ◽  
Ika Arum Dewi Satiti ◽  
Nashi Widodo ◽  
Mifetika Lukitasari ◽  
Hidayat Sujuti

Renin catalyzes the cleavage of angiotensinogen into angiotensin I. Genetic variant C-5312T of renin enhancer has been reported to increase in vitro renin gene transcription. However, no obvious in vivo study was performed to see the renin level in C-5312T when treated with angiotensin receptor blockers (ARB). Therefore, this study aimed to investigate the serum renin level and blood pressure response in ARB treated hypertensive patients. Single nucleotide polymorphism (SNP) of C-5312T was identified in 55 hypertensive patients by using multiplex PCR and renin serum level was assayed by ELISA. The data showed that the increase of serum renin levels after 5 months of ARB treatment was significantly higher in patients with CT/TT genotype (10 pg/mL) than those with CC genotype (4.08 pg/mL) (P= 0.025). Hypertensive patients with CT/TT genotypes also showed less diastolic pressure reduction than CC genotypes in hypertensive patients with valsartan treatment (P= 0.04) or telmisartan treatment (P= 0.03). Finally, these findings suggested that SNP of C-5312TRENenhancer might contribute to higher increased renin serum levels and less diastolic blood pressure response to ARB treatment.


2013 ◽  
Vol 31 (6) ◽  
pp. 1233-1238 ◽  
Author(s):  
Ryo Sato ◽  
Masashi Mizuno ◽  
Toshiyuki Miura ◽  
Yoko Kato ◽  
Shuichi Watanabe ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
pp. e13-e13
Author(s):  
Ahmadreza Maghsoudi ◽  
Maryam Dehghani Mobarakeh ◽  
Ali Momeni ◽  
Alireza Nematollahi ◽  
Shahin Asgari ◽  
...  

Introduction: Hypertension is one of the most leading causes of death worldwide. It is an important risk factor for ischemic heart disease (IHD), chronic kidney disease (CKD) and cerebrovascular diseases. Objectives: The aim of the study was evaluation of the status of blood pressure control and trends in prescribed antihypertensive medication usage among hypertensive patients in Shahrekord, Iran. Patients and Methods: In a cross-sectional descriptive study 250 hypertensive patients were enrolled. The patients were evaluated based on the status of blood pressure (BP) control and the prescription trends and efficacy of antihypertensive drugs. The data were also evaluated in subgroups of diabetics or non-diabetics, smokers or non-smokers, patients with or without CKD, patients with or without IHD. Results: A total of 250 patients (149 women and 101 men) were enrolled in this study. The mean age of participants was 66.22±13.58 years. Mean systolic and diastolic BP were 143.4±29.4 mm Hg and 85.8±12.5 mm Hg respectively. Poor controlled BP was seen in 106 patients. The more common prescribed antihypertensive drugs were angiotensin receptor blockers (46%), diuretics (33.6%) and beta-blockers (32.8%). Conclusion: The study showed that most of the patients had poor controlled BP and physicians increasingly prescribe angiotensin receptor blockers.


Author(s):  
Rajashree Samal ◽  
Jyoti Prakash Panda ◽  
Kali Prasad Pattnaik

Background: Interventions that target blood pressure control and proteinuria, specifically interruption of the Renin-angiotensin-aldosterone system (RAAS), have been utilized in attenuating cardiovascular complications. Angiotensin receptor blockers (ARBs) have been reported to have certain advantages. The objective of the study was to evaluate and compare the utilization pattern and efficacy of different ARBs in patients with HTN and associated type-II diabetes.Methods: Hypertensive patients with or without type-II diabetes treated with ARB based regimen were selected.  The BP and 24 hours urinary albumin excretion were analysed at baseline and after three months of treatment.Results: Mean reduction in systolic blood pressure(SBP) was more with ARBs and calcium channel blocker(CCB) combination. Telmisartan alone and with ACEI reduced diastolic blood pressure (DBP) maximally in diabetic hypertensive patients. Proteinuria was significantly reduced with telmisartan (p<0.001) and olmesartan (p<0.05) based therapy. The side effects were minimal with ARB based therapy. Telmisartan was the costliest among all ARBsConclusions: There was suboptimal use of combination therapy in diabetic hypertensive patients.  Telmisartan was having the better control on 24hr urinary albumin excretion.


2005 ◽  
Vol 6 (1_suppl) ◽  
pp. S8-S11
Author(s):  
Hans-Christoph Diener

Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention. All antihypertensive drugs are effective in primary prevention: the risk reduction for stroke is 30—42%. However, not all classes of drugs have the same effects: there is some indication that angiotensin receptor blockers may be superior to other classes of antihypertensive drugs in stroke prevention. Seventy-five percent of patients who present to hospital with acute stroke have elevated blood pressure within the first 24—48 hours. Extremes of systolic blood pressure (SBP) increase the risk of death or dependency. The aim of treatment should be to achieve and maintain the SBP in the range 140—160 mmHg. However, fast and drastic blood pressure lowering can have adverse consequences. The PROGRESS trial of secondary prevention with perindopril + indapamide versus placebo + placebo showed a decrease in numbers of stroke recurrences in patients given both active antihypertensive agents, more impressive for cerebral haemorrhage.There were also indications that active treatment might decrease the development of post-stroke dementia.


Author(s):  
Santenna Chenchula ◽  
Rupesh Gupta ◽  
Balakrishnan S. ◽  
Akash Vishwe ◽  
Pushparaj Gour ◽  
...  

Background: There are many groups of drugs to decrease microalbuminuria like angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), calcium channel blockers and direct vasodilators. Among these, ACEI and ARBs are commonly used for this purpose. If side effects occur, ACEI are replaced with ARBs. Many ARBs have been studied for their effect on reducing microalbuminuria, but data on telmisartan with its additional unique properties are scarce in Indian population.Methods: This cross sectional observational study was carried out in a tertiary care centre. We first measured base line urine albumin levels in included patients, 3 months after treatment with telmisartan using ‘hemocue urine albumin analyser’. We collected and compared both baseline and after treatment data of microalbuminuria and analysed in descriptive statistics.Results: A total of 110 patients participated in this study; out of which 10 patients were excluded from the study because they were not available for follow up. As compared to baseline, urine albumin level decreased by 30.42% after 12 weeks treatment with telmisartan (P <0.001).Conclusions: Microalbuminuria is one of the leading cause of end stage renal disease and coronary heart diseases in diabetic hypertensive patients. Drugs like ACE inhibitors, Angiotensin receptor blockers, Calcium channel blockers and direct vasodilators are used to prevent these complications. In this present study, we concluded that telmisartan decreases urine albumin excretion around 30.42% from baseline after 12 weeks of treatment.


Sign in / Sign up

Export Citation Format

Share Document